AI drug discovery company

BigHat Biosciences

Data as of Oct 17, 2026.

Company facts

Founded

2019

ReportedSource for founded (opens in new tab)
Headquarters

United States (San Mateo, CA)

ConfirmedSource for headquarters (opens in new tab)
Total funding

$223M

ConfirmedSource for total funding (opens in new tab)

Latest funding round

Round: Series C
Date: Sep 24, 2026
Amount: $75M
Lead investor: DFJ Growth and Premji Invest (co-leads)

ConfirmedSource for the latest round (opens in new tab)

Drugs on the board

BHB810

Phase 1/2 registry

CDH17-positive gastrointestinal cancers (gastric, gastroesophageal junction, colorectal, pancreatic)

Registry for BHB810 (opens in new tab)

Recent news

Sep 24, 2026

Series C: $75M

ConfirmedSource (opens in new tab)
May 26, 2026

STAT interview with CEO Peyton Greenside

ReportedSource (opens in new tab)

Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.

Spot an error? Tell me and I'll fix it.